Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time, setting up regulatory filings.

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan ...